Bioanalysis

  • Bioanalysis
  • Since 2004, the average cost of bringing a new drug to market has increased from $800 million to about $2.6 billion, without, for the most part, shorter development time

    Application of Mitra Microsampling for the Quantitative Bioanalysis of Antisense Oligonucleotides

    Current Strategies for Using Commercial LBA Kit in Regulated Bioanalysis

    Biologics are large, complex molecules that can undergo structural changes during the manufacturing process, storage, or administration to patients. This means bioanalysis of biologics is a critical aspect of the drug development process, and one that requires sensitivity, specificity, and selectivity.

    Microsampling Podcast - Breakthrough Novel Application for the Analysis of ASOs

    Coupling Hybridization LC-MS Workflows with Microsampling for the Analysis of Antisense Oligonucleotides

    Join Altasciences’ scientific experts as they discuss novel LC-MS-based strategies and workflows for the quantitative bioanalysis of oligonucleotide therapeutics (ASO) via dried blood microsampling.

    Discover how this breakthrough novel application can:

    • be applied to nonclinical studies
    • facilitate remote sample collection for patient-centric trials
    • eliminate the tedious and often error-prone approach that occurs when using liquid-based capillary microsampling

    Speak with one of our experts to learn more about our service offering.

    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.

    Have five minutes? Take a look at these:

    Hybridization LC-MS/MS Workflow to Quantify an siRNA Drug Candidate in Plasma, CSF, and Tissues

    Overcome Matrix Shortage and Non-specific Binding Issues

    Surrogate Cerebrospinal Fluid Method for ASO Quantitation

    In this presentation, we identify a suitable surrogate matrix to overcome issues regarding the shortage of nonhuman primate matrices, and susceptibility to non-specific binding (inherent in the analysis of oligonucleotides), including the use of artificial cerebrospinal fluid.

    Listen to the presentation!

    You may also be interested in the following:

    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.

    Accelerate Your Data with Our Co-located Clinic and Lab

    Ensuring Chain of Custody from Clinic to Lab

    Did you know that our Canadian clinical facility is only a 15-minute drive from our bioanalytical facility?

    This two-minute video provides an overview of our workflows, optimized to ensure timely collection, processing, transport, and rapid analysis of your samples for expedited go/no-go decision-making. Altasciences’ highly trained clinical staff and lab analysts understand the time-sensitive nature of your projects. Real-time access to essential data is our top priority.

    Watch Now

    Speak with one of our experts to learn more about our solution and how we can support your program.

    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.

    Have five minutes? Take a look at these:

    Benefits of Increasing Automation in the Lab

    In this webinar, learn about the extent of automation within bioanalysis in today’s landscape, the practicality of automated technologies for extraction methods and ligand binding assays, and future projections for bioanalytical automation.

     

    Speak with an expert about your research needs.

    You may also be interested in the following:

    Subscribe to Bioanalysis